Screener
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Maravai LifeSciences Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Maravai LifeSciences Holdings, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:03 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001823239-26-000059
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Gross profit | 20,650 | 7,768 | 54,351 | 15,493 |
| Operating expenses: | ||||
| Selling, general and administrative | 32,070 | 38,715 | 61,162 | 78,279 |
| Research and development | 3,702 | 4,882 | 7,591 | 9,770 |
| Goodwill impairment | — | 30,449 | — | 42,884 |
| Restructuring | (33) | — | 2,845 | — |
| Total operating expenses | 35,739 | 74,046 | 71,598 | 130,933 |
| Loss from operations | (15,089) | (66,278) | (17,247) | (115,440) |
Item 1. Financial Statements
FAQ
- What is Maravai LifeSciences Holdings, Inc.'s R&D?
- Maravai LifeSciences Holdings, Inc. (MRVI) reported R&D of $3.7M in Q2 2026.
- How has Maravai LifeSciences Holdings, Inc.'s R&D changed year-over-year?
- Maravai LifeSciences Holdings, Inc.'s R&D decreased by 24.2% year-over-year, from $4.88M to $3.7M.
- What is the long-term trend for Maravai LifeSciences Holdings, Inc.'s R&D?
- Over 4 years (2021 to 2025), Maravai LifeSciences Holdings, Inc.'s R&D has grown at a 3.4% compound annual growth rate (CAGR), from $15.22M to $17.4M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Maravai LifeSciences Holdings, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude